Epidemiology of Immunoglobulin Resistant Kawasaki Disease: Results from a Large, National Database

Pediatric Cardiology

Volumn 36, Issue 2, 2015, Pages 374-378

  Moffett, Brady S ^a,b   Syblik, Dorothy ^a   Denfield, Susan ^b   Altman, Carolyn ^b   Tejtel Sexson, Kristin ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; IVIG; Kawasaki disease; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; CORTICOSTEROID; IMMUNOGLOBULIN G; INFLIXIMAB; METHYLPREDNISOLONE; PENTOXIFYLLINE; RITUXIMAB; WARFARIN; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

AFRICAN AMERICAN; ARTICLE; CHILD; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL READMISSION; HUMAN; ICD-9; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEDIATRIC HOSPITAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; DRUG RESISTANCE; INFANT; TREATMENT OUTCOME;

DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME;

EID: 84921744858     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-014-1016-1     Document Type: Article

References (14)

1. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17(12):1144–1148
2. Chang RK (2002) Epidemiologic characteristics of children hospitalized for Kawasaki disease in California. Pediatr Infect Dis J 21(12):1150–1155
3. Fukunishi M, Kikkawa M, Hamana K et al (2000) Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 137(2):172–176
4. Ghelani SJ, Sable C, Wiedermann BL, Spurney CF (2012) Increased incidence of incomplete Kawasaki disease at a pediatric hospital after publication of the 2004 American Heart Association guidelines. Pediatr Cardiol 33(7):1097–1103
5. Hwang JY, Lee KY, Rhim JW et al (2011) Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child 96(11):1088–1090
6. Kahwaji IY, Connuck DM, Tafari N, Dahdah NS (2002) A national survey on the pediatric cardiologist’s clinical approach for patients with Kawasaki disease. Pediatr Cardiol 23(6):639–646
7. Kobayashi T, Inoue Y, Takeuchi K et al (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113(22):2606–2612
8. Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114(6):1708–1733
9. Porcalla AR, Sable CA, Patel KM, Martin GR, Singh N (2005) The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms? Pediatr Cardiol 26(6):775–781
10. Seki M, Kobayashi T, Kobayashi T et al (2011) External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease. Pediatr Infect Dis J 30(2):145–147
11. Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C (2006) Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singap Med J 47(9):780–784
12. Son MB, Gauvreau K, Ma L et al (2009) Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 124(1):1–8
13. Son MB, Gauvreau K, Burns JC et al (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 158(4):644–649
14. Tremoulet AH, Best BM, Song S et al (2008) Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 153(1):117–121